Recently, Hygieia Pharmaceuticals Co., Ltd. (hereinafter referred to as "Hygieia") completed nearly RMB 100 million in A1 round financing. This round of financing was led by Tasly Capital, with follow-up investments from Heda Health and Shanghai Jianxin Capital, and existing shareholders continued to increase their investment. After this round of financing, Hygieia will accelerate the progress of the company's clinical-stage pipeline research and advance preclinical compounds (PCCs) towards IND filing.
Hygieia Pharmaceuticals Co., Ltd. was founded in 2021, focusing on the construction of a technology platform for siRNA delivery and drug development. It has established a complete end-to-end siRNA drug development platform from target discovery to clinical Proof of Concept (POC). The company boasts a professional team with extensive experience covering the entire lifecycle from early research to industrialization. With over 20 years of industry experience, the R&D team has successfully advanced multiple products into the clinical translation stage, and some pipelines have achieved Best in Class validation in human trials.
Hygieia has developed multiple siRNA delivery technology platforms with fully independent intellectual property rights. Based on these siRNA delivery technology platforms, the company focuses on disease areas with urgent clinical needs or no available treatments. Its pipeline covers hepatitis B, NASH/MASH, cardiovascular and metabolic diseases, complement-mediated related diseases, and neurological disorders.
Among them, the MVIP delivery platform developed by Hygieia is the world’s first dual-conjugate siRNA delivery technology for liver-derived diseases, featuring unique stability that prevents siRNA degradation. Its high efficiency, safety, and long-lasting effects have been validated through multiple pipelines of Hygieia's clinical and preclinical studies. Additionally, the MVIP delivery platform is also the first siRNA delivery technology platform in China to receive global patent authorization.